Biocon Biologics outlicenses two biosimilar assets to Yoshindo for commercialisation in Japan
bUstekinumab and bDenosumab to address market opportunity of approximately $700 million
Biocon Biologics today entered into a strategic out-licensing agreement with Japanese pharma company Yoshindo for commercialising two of its pipeline biosimilar assets, bUstekinumab and bDenosumab, in the Japanese market, a company statement informed.
The statement said that under the terms of this deal, Yoshindo gets exclusive commercialiasation rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics, for an addressable market opportunity of approximately $700 million.
Biocon Biologics will receive an upfront license fee as well as additional payments on the achievement of certain development milestones over the next few years. The financial terms of the agreement are confidential. Ustekinumab, a biosimilar referencing Stelara, is a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Denosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
Further, according to the statement, the strategic partnership with Yoshindo will build upon Biocon Biologics’ successful progress in its global development programs for these two biosimilar assets. Clinical trials for these two assets commenced in FY22 and include both phase-I and phase-III clinical trials backed by robust pre-clinical CMC packages.